Registration
|
08:15 - 08:50 |
Welcome note from MarketsandMarkets
|
08:50 - 08:55 |
Opening remarks from the Chairman
|
08:55 - 09:00 |
CLINICAL BIOMARKER DRUG DEVELOPMENT AND PRECISION MEDICINE |
Aligning Innovation with Precision Medicine
Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca
|
09:00 - 09:30 |
Gene expression signatures: key success factors
Eike Staub, Head, Oncology Bioinformatics, Merck Healthcare, Germany
|
09:30 - 10:00 |
Transforming Oncology with Predicine’s Liquid Biopsy Solutions
Shidong Jia, Founder, CEO, Predicine
|
10:00 - 10:30 |
Morning Refreshments and Poster Presentation | One-to-One Networking Meetings
|
10:30 - 11:15 |
Solution Provider Presentation
|
11:15 - 11:45 |
Analysis of biomarkers in circulating fluids-emerging trend in liquid biopsy
|
11:45 - 12:15 |
Precision Proteomic Landscape of health-to-disease transitions of Rheumatic Musculoskeletal disorders and links to Cancer associate irAEs
Allan Stensballe, Associate Professor, Aalborg University
|
12:15 - 12:45 |
Lunch and Poster Presentation | One-to-One Networking Meeting
|
12:45 - 13:45 |
Why do 95% of oncology drugs fail in clinical development, and how can biomarkers help?
Philip Beer, Chief Scientific Officer, Step Pharma
|
13:45 - 14:15 |
Use of omics technologies in biomarker discovery and profiling
|
14:15 - 14:45 |
Precision medicine in rare diseases – learnings and opportunities
Thomas Hach, Executive Director Patient Engagement, Cardiovascular, Renal & Metabolism Patient Engagement, Novartis
|
14:45 - 15:15 |
Evening Refreshments and Poster Presentation | One-to-One Networking Meetings
|
15:15 - 15:45 |
Digital Biomarkers, Predictive Biomarkers, Precision Medicine, and Big Data
Katarzyna Wac, Full Professor, Computer Science, University of Geneva
|
15:45 - 16:15 |
When over 99% of published Biomarkers end up in the bin what can we do to reduce this waste and pick out the ones that could be rescued?
Christopher Peters, Clinical Senior Lecturer, Imperial College London
|
16:15 - 16:45 |
Panel Discussion: Clinical biomarker development is critical to bring precision medicine from a scientific concept into clinical practice-Views?
Louis Boon, CSO , JJP Biologics
Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca
Vaios Karanikas, Biomarker Experimental Medicine Leader, Oncology, Roche
Christopher Peters, Clinical Senior Lecturer, Imperial College London
|
16:45 - 17:15 |
Closing Remarks from the Chairperson
|
17:15 - 17:15 |
Drinks Reception & Networking
|
17:15 - 17:15 |
End of Day 1
|
17:15 - 17:15 |